New Alzheimer’s Treatment Would Cost $26,500 Per Year

Signage outside of the Food and Drug Administration headquarters in White Oak, Md., on Aug. 29, 2020. Andrew Kelly/Reuters

A new Alzheimer’s treatment would cost patients an estimated $26,500 per year, said the drug developer.

The Food and Drug Administration (FDA) announced on Jan. 6 that it would grant accelerated approval to Biogen and Eisai, after the drug appeared to partially slow the development of mild cases of Alzheimer’s disease in clinical trials.